A detailed history of Manufacturers Life Insurance Company, The transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 50,368 shares of DAWN stock, worth $690,545. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,368
Previous 40,878 23.22%
Holding current value
$690,545
Previous $596,000 39.6%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$13.56 - $17.46 $128,684 - $165,695
9,490 Added 23.22%
50,368 $832,000
Q4 2023

Feb 13, 2024

SELL
$9.68 - $15.37 $5,207 - $8,269
-538 Reduced 1.3%
40,878 $596,000
Q3 2023

Nov 15, 2023

SELL
$11.22 - $14.86 $250,172 - $331,333
-22,297 Reduced 35.0%
41,416 $508,000
Q2 2023

Aug 11, 2023

BUY
$11.74 - $14.47 $53,522 - $65,968
4,559 Added 7.71%
63,713 $760,000
Q1 2023

May 15, 2023

SELL
$12.75 - $23.41 $49,788 - $91,416
-3,905 Reduced 6.6%
55,249 $738,000
Q4 2022

Aug 11, 2023

BUY
$18.77 - $22.0 $31,852 - $37,334
1,697 Added 2.95%
59,154 $1.27 Million
Q4 2022

Feb 13, 2023

BUY
$18.77 - $22.0 $31,852 - $37,334
1,697 Added 2.95%
59,154 $1.27 Million
Q3 2022

Aug 11, 2023

SELL
$16.44 - $26.57 $2,548 - $4,118
-155 Reduced 0.27%
57,457 $1.15 Million
Q3 2022

Nov 03, 2022

SELL
$16.44 - $26.57 $2,548 - $4,118
-155 Reduced 0.27%
57,457 $1.13 Million
Q2 2022

Aug 11, 2023

BUY
$5.72 - $17.9 $82,568 - $258,386
14,435 Added 33.43%
57,612 $1.03 Million
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $82,568 - $258,386
14,435 Added 33.43%
57,612 $1.02 Million
Q1 2022

Aug 11, 2023

SELL
$9.12 - $17.47 $110,096 - $210,897
-12,072 Reduced 21.85%
43,177 $428,000
Q1 2022

May 20, 2022

BUY
$9.12 - $17.47 $393,774 - $754,302
43,177 New
43,177 $425,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.01B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.